Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$83,609.00-3.08%ETH$2,579.18-4.97%GOLD$4,148.90-0.91%OIL$89.83+0.44%
Smart Investors Daily
SID Premium
XC

NASDAQ · XCUR

Exicure, Inc.

Healthcare · Biotechnology

$1.08

Up+$0.01 (+0.93%)

Updated Oct 7, 2026, 10:31 AM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
39.07M
P/E ratio
-4.91
Dividend yield
0.00%
52-week range
$1.05 – $9.48
Volume
7.34K
Avg. volume
653.33K

Price performance · XCUR

XCUR price history

1M range · 0 trading sessions · Daily adjusted prices

XCUR does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest XCUR news

The latest Smart Investors Daily articles mentioning XCUR.

Stock researchCompany · Overview

XCUR research

Overview

Company profile and research snapshot.

Company profile

Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$12.00
Implied upside
—
Analysts
6
XCUR recent ratings
DateFirmRatingTarget
Aug 16, 2022Chardan CapitalNeutral—
Dec 13, 2021Chardan CapitalNeutral—
Nov 23, 2021Chardan CapitalBuy—
May 17, 2021HC Wainwright & Co.Buy—
Dec 18, 2020BMO CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 16, 2026

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

WILMINGTON, Del., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that, on September 10, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension through December 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(b)(1). As previously disclosed, on June 5, 2026, Nasdaq notified the Company that it did not satisfy Nasdaq Listing Rule 5550(b)

Yahoo · Aug 3, 2026

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement. The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including th

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By